Literature DB >> 2458855

Elevation of polycyclic aromatic hydrocarbon-inducible aryl hydrocarbon hydroxylase activity in rat hepatocytes in primary culture by inhibitors of poly(ADP-ribose) polymerase.

N Nemoto1, T Ishikawa.   

Abstract

Induction of aryl hydrocarbon hydroxylase (AHH) activity was studied in primary cultures of rat hepatocytes. AHH activity was induced by treatment with benz[a]anthracene and combined treatment with cycloheximide for an initial short period during the induction enhanced benz[a]anthracene-inducible AHH activity. The enhancement was correlated to amounts of cytochrome P-450 RNA, indicating that cycloheximide treatment increased transcription of benz[a]anthracene-inducible cytochrome P-450 gene species. 3-Methoxybenzamide and 3-aminobenzamide, known to be physiologically specific inhibitors for poly(ADP-ribose) polymerase, but not the structurally related non-inhibitor, 3-aminobenzoic acid, also increased benz[a]anthracene-induced AHH activity. In addition, 3-methoxybenzamide was found to further increase the enhancing effects of cycloheximide on benz[a]anthracene induction of AHH. The effects of poly(ADP-ribose) polymerase inhibitors were not mediated by reduction of cyclic nucleotide phosphodiesterase activity. This was in clear contrast to the situation with the xanthine derivative, aminophylline, which also brought about a similar enhancement of AHH induction by benz[a]anthracene. The results suggest the participation of poly(ADP-ribose) in the regulation of expression of benz[a]anthracene-inducible cytochrome P-450 genes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458855     DOI: 10.1093/carcin/9.10.1823

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  1 in total

1.  Proline is required for transcriptional control of the aromatic hydrocarbon-inducible P(1)450 gene in C57BL/6 mouse monolayer-cultured hepatocytes.

Authors:  N Nemoto; J Sakurai
Journal:  Jpn J Cancer Res       Date:  1991-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.